Skip to main content
Log in

Neuroleptic malignant syndrome during haloperidol treatment in a cancer patient

A case report

  • SHORT COMMUNICATION
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

A case of neuroleptic malignant syndrome (NMS) in a 64-year-old man with cancer of the soft palate is reported. During haloperidol treatment for delirium, the patient showed consciousness disturbance with extrapyramidal signs. With discontinuation of haloperidol and replacement by dantrolene and bromocriptine, the patient recovered completely. Although major tranquilizers are widely used in clinical oncology to manage symptoms, NMS has been rarely reported in cancer patients, presumably because of lack of awareness. Early recognition of NMS and prompt treatment may improve the potentially fatal outcome.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tanaka, K., Akechi, T., Yamazaki, M. et al. Neuroleptic malignant syndrome during haloperidol treatment in a cancer patient . Support Care Cancer 6, 536–538 (1998). https://doi.org/10.1007/s005200050211

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s005200050211

Navigation